Back to search

Article

Immunogenicity and reactogenicity of SARS-CoV-2 mRNA and inactivated vaccines in healthy adolescents

2022-03-08

Abstract excerpt

<title>Abstract</title> <p>For SARS-CoV-2 vaccines, efficacy data for BNT162b2 but not CoronaVac are available in adolescents. Phase II/III studies focused on neutralizing antibody responses in adolescents, neglecting binding antibody and cellular responses that are also important against SARS-CoV-2. Therefore, we conducted a registered clinical study (NCT04800133) to establish immunobridging with various antibod...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
16c2e26c-d48b-5881-ab81-d5a8dd5466ec
DOI
10.21203/rs.3.rs-1327020/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immunogenicity and reactogenicity of SARS-CoV-2 mRNA and inactivated vaccines in healthy adolescentsDOI 10.21203/rs.3.rs-1327020/v1
Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after the third dose of BNT162b2 in healthy adolescentsSemantic proximity
Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVacSemantic proximity
Immunologic response, Efficacy, and Safety of Vaccines Against COVID-19 Infection in Children and Adolescents Aged 2 – 21 years old: A Systematic ReviewSemantic proximity
Safety of the BNT162b2 mRNA COVID-19 Vaccine in Children below 5 Years (CoVacU5) – an Investigator-Initiated Retrospective Cohort StudySemantic proximity
Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using two-dose primary protocol in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow upSemantic proximity
Real-world Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and AdolescentsSemantic proximity
Immunogenicity Against Wild-Type and Omicron SARS-CoV-2 After a Third Dose of Inactivated COVID-19 Vaccine in Healthy AdolescentsSemantic proximity
Age- and sex-specific differences in immune responses to BNT162b2 COVID-19 and live-attenuated influenza vaccines in UK adolescentsSemantic proximity
Sex differences in symptoms following the administration of BNT162b2 mRNA Covid-19 Vaccine in Children below 5 Years of age in Germany (CoVacU5): a retrospective cohort studySemantic proximity
Cellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patientsSemantic proximity
Humoral and Cellular Immunogenicity and Safety of 3 Doses of CoronaVac and BNT162b2 in Young Children and Adolescents with Kidney DiseasesSemantic proximity
HUMORAL AND CELLULAR IMMUNOGENICITY and SAFETY UP TO 4 MONTHS AFTER VACCINATION WITH BNT162B2 mRNA COVID-19 VACCINE IN HEART AND LUNG TRANSPLANTED YOUNG ADULTSSemantic proximity
Select a neighboring publication to make it the new centre.